Blueprint Medicines (NASDAQ:BPMC) reported Q4 2017 earnings this Morning, coming in at ($1.23) per share, missing Wall Street’s estimates of ($1.07) per Share. Revenue for the quarter came in at $1.63 million missing the streets estimates of $5.28 million Recent Insider Trading for Blueprint Medicines (NASDAQ:BPMC)
- On 2/14/2018 Daniel Lynch, Director, sold 12,500 with an average share price of $80.42 per share and the total transaction amounting to $1,005,250.00.
- On 2/12/2018 Daniel Lynch, Director, sold 17,500 with an average share price of $74.84 per share and the total transaction amounting to $1,309,700.00.
- On 2/12/2018 Kate Haviland, Insider, sold 6,775 with an average share price of $74.93 per share and the total transaction amounting to $507,650.75.
- On 11/21/2017 Marion Dorsch, Insider, sold 18,334 with an average share price of $65.45 per share and the total transaction amounting to $1,199,960.30.
- On 11/15/2017 Daniel Lynch, Director, sold 5,000 with an average share price of $63.38 per share and the total transaction amounting to $316,900.00.
- On 11/6/2017 Anthony L Boral, Insider, sold 5,000 with an average share price of $70.40 per share and the total transaction amounting to $352,000.00.
Recent Trading for Blueprint Medicines (NASDAQ:BPMC) Shares of Blueprint Medicines closed the previous trading session at 81.57 down -0.27 0.33% with 81.56999969482422 shares trading hands.